Vectus Biosystems Limited (AU:VBS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vectus Biosystems Limited has made significant strides in the commercialization of its clinical drug VB0004 and other assets, with expectations of reduced operating costs and a potential R&D refund from the ATO in October 2024. The company has completed Phase Ib human clinical trials for VB0004 with no significant adverse events reported and is progressing on a formal outreach program for licensing and partnerships. Despite the passing of CEO Dr. Karen Duggan, Vectus remains committed to advancing its anti-fibrotic technologies and fulfilling its mission.
For further insights into AU:VBS stock, check out TipRanks’ Stock Analysis page.